Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 177Lu-Vipivotide Tetraxetan
NCT06099093Phase 4Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of piflufolastat f 18 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Brigham and Women's Hospital. Started Apr 2024; status: recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06099093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099093.